Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 57 73
Helicobacter Pylori Infection, Susceptibility to 57 29 6 40
H. Pylori Infection, Susceptibility to 57 13
Helicobacter Pylori Infections 43
H. Pylori Infection 57

Characteristics:

OMIM:

57
Inheritance:
not determined


Classifications:



External Ids:

OMIM 57 600263
MedGen 42 C1838332
UMLS 73 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus : 43 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to atrophic gastritis and duodenal ulcer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Acetylcysteine and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and kidney, and related phenotypes are helicobacter pylori infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 57 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 atrophic gastritis 32.2 CXCL8 GAST IL1B
2 duodenal ulcer 32.0 CXCL8 CYP2C19 GAST IL1B
3 peptic ulcer disease 32.0 CXCL8 CYP2C19 GAST IL1B
4 gastritis 31.9 CXCL1 CXCL8 GAST IL1B MUC6
5 gastric ulcer 31.7 CXCL8 CYP2C19 GAST IL1B
6 gastroesophageal reflux 31.6 CXCL8 CYP2C19 GAST IL1B
7 esophagitis 31.5 CXCL8 CYP2C19 EGFR IL1B
8 idiopathic neutropenia 30.5 CASP3 CCL5 IL1B
9 respiratory system disease 30.2 CCL5 CXCL8 IL1B
10 gastrointestinal system disease 30.1 CXCL8 GAST IL1B
11 gastric adenocarcinoma 29.9 CASP3 CXCL8 EGFR GAST IL1B JUN
12 t-cell leukemia 29.0 CASP3 CHUK JUN NFKBIA
13 rheumatoid arthritis 28.1 CCL5 CXCL1 CXCL8 IL1B JUN
14 gastric cancer 11.7
15 gastric cancer, hereditary diffuse 11.2
16 mycobacterium fortuitum 10.9 CXCL8 IFNGR1
17 recurrent corneal erosion 10.9 CXCL8 IL1B
18 peptic esophagitis 10.8 CXCL8 CYP2C19 IL1B
19 stomach disease 10.8 CXCL8 GAST IL1B
20 bagassosis 10.8 CXCL8 IL1B
21 osteomyelitis 10.8 CXCL8 IFNGR1 IL1B
22 duodenitis 10.7
23 lymphadenitis 10.7 CASP3 CXCL8 IFNGR1 IL1B
24 adenocarcinoma 10.6
25 mucositis 10.6
26 lymphoma 10.5
27 salivary gland cancer 10.5 CASP3 EGFR MET
28 aging 10.5
29 dyspepsia 10.5
30 visceral leishmaniasis 10.5 CXCL8 IFNGR1 IL1B
31 viral encephalitis 10.5 CCL5 CXCL8 IL1B
32 meningitis 10.5 CXCL1 CXCL8 IL1B
33 extrinsic allergic alveolitis 10.4 CCL5 CXCL8 IL1B
34 respiratory system cancer 10.4 CASP3 EGFR MET
35 autoinflammation, lipodystrophy, and dermatosis syndrome 10.4 CCL5 CXCL8 IL1B
36 salmonellosis 10.4 IFNGR1 IL1B JUN
37 gastric lymphoma 10.4
38 iron metabolism disease 10.4
39 purpura 10.4
40 bronchial disease 10.3 CCL5 CXCL8 IFNGR1 IL1B
41 deficiency anemia 10.3
42 iron deficiency anemia 10.3
43 lymphoma, mucosa-associated lymphoid type 10.3
44 trypanosomiasis 10.3 CCL5 CXCL8 IL1B
45 pancreatitis 10.3
46 gastroduodenitis 10.3
47 gastrointestinal system cancer 10.3 CASP3 EGFR MET
48 diabetes mellitus 10.2
49 interstitial lung disease 10.2 CCL5 CXCL8 EGFR IL1B
50 laryngitis 10.2

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Symptoms via clinical synopsis from OMIM:

57
GI:
helicobacter pylori infection susceptibility


Clinical features from OMIM:

600263

Human phenotypes related to Helicobacter Pylori Infection:

32
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 32 HP:0005202

UMLS symptoms related to Helicobacter Pylori Infection:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 NFKBIA CASP3 NOD1 CHUK CXCL8 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 NFKB1 NFKBIA CASP3 NOD1 CHUK CXCL8

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.34 ADAM10 CASP3 CCL5 CHUK EGFR GAST
2 hematopoietic system MP:0005397 10.29 PAK1 PTPN11 ADAM10 CASP3 CCL5 CHUK
3 cellular MP:0005384 10.28 ADAM10 CASP3 CHUK EGFR IFNGR1 JUN
4 homeostasis/metabolism MP:0005376 10.27 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
5 cardiovascular system MP:0005385 10.25 JUN MET PAK1 PTPN11 ADAM10 CASP3
6 endocrine/exocrine gland MP:0005379 10.24 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
7 digestive/alimentary MP:0005381 10.16 MET NFKB1 PTPN11 IFNGR1 ADAM10 CASP3
8 craniofacial MP:0005382 10.13 CHUK EGFR IL1B MET NFKB1 PTPN11
9 integument MP:0010771 10.1 CASP3 CHUK EGFR IFNGR1 IL1B JUN
10 nervous system MP:0003631 10.03 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
11 liver/biliary system MP:0005370 9.91 CHUK EGFR IFNGR1 JUN MET NFKB1
12 neoplasm MP:0002006 9.87 CHUK EGFR GAST IFNGR1 IL1B MET
13 normal MP:0002873 9.81 ADAM10 EGFR JUN MET NFKB1 NFKBIA
14 respiratory system MP:0005388 9.56 CASP3 CHUK EGFR JUN MET NFKB1
15 skeleton MP:0005390 9.32 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
2
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 26787-78-0 33613
3
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138530-94-6, 103577-45-3 9578005
5
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 103577-45-3 3883
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
7
Metronidazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 443-48-1 4173
8
Pantoprazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 102625-70-7 4679
9
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
10
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
11
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
12
Tetracycline Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-54-8 5353990
13
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100986-85-4 149096
14
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82419-36-1 4583
15
Furazolidone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 67-45-8 3435 5323714
16
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
17
Bismuth Subsalicylate Approved, Vet_approved Phase 4,Phase 3,Phase 2 14882-18-9 53629521
18
Loperamide Approved Phase 4,Phase 3,Phase 2 53179-11-6 3955
19
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable
20
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2 19387-91-8 5479
21
Coal tar Approved Phase 4 8007-45-2
22 Titanium dioxide Approved Phase 4 13463-67-7
23
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
24
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 564-25-0 54671203
25
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
26
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
27
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 1406-66-2 14986
28
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-81-7 5785 54670067
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-02-9 14985
30
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 77-92-9 311
31
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
32
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antidotes Phase 4
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antioxidants Phase 4
37 Antiviral Agents Phase 4
38 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Expectorants Phase 4,Phase 3
41 N-monoacetylcystine Phase 4,Phase 1,Phase 2
42 Protective Agents Phase 4,Phase 2
43 Respiratory System Agents Phase 4,Phase 3
44 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Not Applicable
46 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Not Applicable
47 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Not Applicable
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
2 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
3 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
4 Tailored Therapy for Helicobacter Pylori in Children Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
5 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
6 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
7 H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
8 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
9 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
10 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
11 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
12 Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
13 Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
14 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
15 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
17 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
18 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
19 Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
20 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
21 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
22 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
23 Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
24 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea Completed NCT01887249 Phase 4 Clarithromycin;metronidazole;esomeprazole
25 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
26 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
27 A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
28 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
29 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4 Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
30 High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
31 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4 Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
32 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
33 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
34 Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
35 Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment Completed NCT02935010 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Amoxicillin;Clarithromycin;Metronidazole;Levofloxacin
36 Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment Completed NCT02732249 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole
37 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) Completed NCT00825630 Phase 4 Lansoprazole (Lanton);Omeprezole (Losec);Pantoprazole(Controloc);Esomeprazole (Nexium)
38 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4 RAK therapy;RBAK therapy
39 RCT: Triple vs Sequential vs Concomitant Therapy H Pylori Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
40 Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. Completed NCT00216450 Phase 4 rabeprazole sodium
41 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
42 Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients Completed NCT02466919 Phase 4 Pantoprazole;Amoxicillin;Metronidazole;Levofloxacin;Clarithromycin
43 Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori Completed NCT01573975 Phase 4 5RA-5RCM;5RA-5RCT;10RCA
44 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
45 Clarithromycin Resistant Tailored Therapy Completed NCT01453036 Phase 4
46 POCone-UBiT-IR300 Pediatric Comparison Study Completed NCT01623154 Phase 4
47 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Recruiting NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
48 Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection Recruiting NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
49 Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice. Recruiting NCT03150394 Phase 4
50 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Recruiting NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin

Search NIH Clinical Center for Helicobacter Pylori Infection

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1 PTPRZ1

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

41
Testes, Colon, Kidney, T Cells, Liver, Thyroid, Heart

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 1178)
# Title Authors Year
1
Potential risk factors and prevalence of Helicobacter pylori infection among adult patients with dyspepsia symptoms in Cameroon. ( 29907086 )
2018
2
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma-author's reply. ( 29644785 )
2018
3
Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis. ( 29266548 )
2018
4
Possible association between Helicobacter pylori infection and vocal fold leukoplakia. ( 29509297 )
2018
5
Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. ( 29388723 )
2018
6
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma. ( 29480547 )
2018
7
Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. ( 29895984 )
2018
8
Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. ( 29880962 )
2018
9
Association between Helicobacter pylori infection and vulvar lichen sclerosus: a clinical comparative study. ( 29336317 )
2018
10
The role of T helper 1-cell response in Helicobacter pylori-infection. ( 29936093 )
2018
11
Diagnosis of Helicobacter pylori infection : AA short review. ( 29959527 )
2018
12
Up-regulated Th17 cell function is associated with increased peptic ulcer disease in Helicobacter pylori-infection. ( 29481961 )
2018
13
Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review. ( 29938864 )
2018
14
Oral Capsaicin Test and Functional Dyspepsia: Any Consideration for Helicobacter pylori Infection and Concomitant Medications? ( 29887603 )
2018
15
Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. ( 29426621 )
2018
16
T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection. ( 29407232 )
2018
17
Influence of Helicobacter pylori infection on periodontitis. ( 29932231 )
2018
18
Deep learning analyzes Helicobacter pylori infection by upper gastrointestinal endoscopy images. ( 29399610 )
2018
19
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. ( 29899426 )
2018
20
Influence of the Degree of Gastric Mucosal Atrophy on the Serum Lipid Levels Before and After the Eradication of Helicobacter pylori Infection. ( 29877271 )
2018
21
Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. ( 29430669 )
2018
22
Helicobacter pylori infection increases sirt2 gene expression in gastric epithelial cells of gastritis patients. ( 29355701 )
2018
23
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. ( 29411724 )
2018
24
Feco-prevalence and risk factors of Helicobacter pylori infection among symptomatic patients at Dessie Referral Hospital, Ethiopia. ( 29879914 )
2018
25
Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy. ( 29355977 )
2018
26
Association of Helicobacter pylori infection with Toll-like receptor-4 Thr399Ile polymorphism increased the risk of peptic ulcer development in North of Iran. ( 29135054 )
2018
27
Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. ( 29345340 )
2018
28
Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection? ( 29888786 )
2018
29
Exploring current status of Helicobacter pylori infection in different age groups of patients with dyspepsia. ( 29368191 )
2018
30
Efficacies of Genotypic Resistance-guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. ( 29964036 )
2018
31
Helicobacter pylori infection in family members of patients with gastroduodenal symptoms. A cross-sectional analytical study. ( 29898010 )
2018
32
Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: A meta-analysis of prospective epidemiologic studies. ( 28816977 )
2017
33
Screening and Treating Helicobacter pylori Infection for Gastric Cancer Prevention on the Population Level. ( 28087975 )
2017
34
Development of lymphocytic gastritis with recurrent Helicobacter pylori infection. ( 28211221 )
2017
35
Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. ( 28066960 )
2017
36
Is There a Link between Clinical Manifestation of Gastric Anisakiasis and Helicobacter pylori Infection? ( 28810728 )
2017
37
TLR5 Polymorphisms rs2072493, rs5744174, and rs5744168 Are Not Genetic Risk Factors for Chronic Helicobacter pylori Infection in Indian Tamils. ( 28742407 )
2017
38
Associations among Gastric Juice pH, Atrophic Gastritis, Intestinal Metaplasia and Helicobacter pylori Infection. ( 28918609 )
2017
39
Combination of Helicobacter pylori infection and the interleukin 8 -251A TA >A A polymorphism, but not the mannose-binding lectin 2 codon 54A GA >A A polymorphism, might be a risk factor of gastric cancer. ( 28558668 )
2017
40
Does Helicobacter pylori infection play a role in susceptibility to Brucellosis? ( 28890508 )
2017
41
Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric cancer. ( 28437803 )
2017
42
Genetic variations of TLR5 gene interacted with Helicobacter pylori infection among carcinogenesis of gastric cancer. ( 28404962 )
2017
43
Analyzing the influence of gastric intestinal metaplasia on gastric ulcer healing in Helicobacter pylori-infected patients without atrophic gastritis. ( 28049442 )
2017
44
Expression analysis of matrix metalloproteinase-13 in human gastric cancer in the presence of Helicobacter Pylori infection. ( 28128735 )
2017
45
Very low rates of Helicobacter pylori infection in organ transplant recipients presenting with peptic ulcer disease. ( 29364094 )
2017
46
Transient receptor potential vanilloid 4 (TRPV4) silencing in Helicobacter pylori-infected human gastric epithelium. ( 27687509 )
2017
47
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer. ( 28700998 )
2017
48
The role of environmental tobacco exposure and Helicobacter pylori infection in the risk of chronic tonsillitis in children. ( 28380174 )
2017
49
Association of the IL-1RN variable number of tandem repeat polymorphism and Helicobacter pylori infection: A meta-analysis. ( 28384207 )
2017
50
Is It a Protective Factor of Helicobacter pylori Infection in Overall Survival of All Gastric Cancer? Evidence from Meta-Analysis. ( 29431063 )
2017

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IFNGR1 IFNGR1, -56C-T single nucleotide variant protective,risk factor

Expression for Helicobacter Pylori Infection

Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 ADAM10 CASP3 CCL5 CHUK CXCL1 CXCL8
2
Show member pathways
14.02 ADAM10 CASP3 CCL5 CHUK CXCL1 CXCL8
3
Show member pathways
14.01 CASP3 CCL5 CHUK CXCL1 CXCL8 EGFR
4
Show member pathways
13.99 CASP3 CHUK EGFR IL1B JUN MET
5
Show member pathways
13.83 ADAM10 CHUK EGFR JUN MET MUC6
6
Show member pathways
13.83 CASP3 CCL5 CHUK CXCL1 CXCL8 EGFR
7
Show member pathways
13.67 CCL5 CHUK CXCL8 EGFR IFNGR1 IL1B
8
Show member pathways
13.57 CASP3 CCL5 CHUK CXCL1 CXCL8 EGFR
9
Show member pathways
13.53 CASP3 CCL5 CXCL1 CXCL8 EGFR JUN
10
Show member pathways
13.41 CASP3 CCL5 CHUK CXCL1 CXCL8 EGFR
11
Show member pathways
13.17 CHUK EGFR JUN MET NFKB1 PAK1
12
Show member pathways
13.17 CASP3 CHUK JUN MET NFKB1 NFKBIA
13
Show member pathways
13.13 CCL5 CHUK CXCL1 CXCL8 IFNGR1 IL1B
14
Show member pathways
13.11 CASP3 CHUK EGFR JUN MET NFKB1
15
Show member pathways
13.06 CASP3 CCL5 CHUK JUN NFKB1 NFKBIA
16
Show member pathways
13.06 CCL5 CHUK CXCL1 CXCL8 JUN NFKB1
17
Show member pathways
13.05 CASP3 CHUK CXCL8 IFNGR1 IL1B NFKB1
18
Show member pathways
13.04 CASP3 CHUK EGFR JUN NFKB1 NFKBIA
19 13 CASP3 CHUK CXCL8 EGFR IFNGR1 JUN
20
Show member pathways
12.98 CHUK IFNGR1 IL1B JUN NFKB1 NFKBIA
21 12.95 CASP3 CHUK EGFR IL1B JUN MET
22
Show member pathways
12.92 CCL5 CHUK CXCL8 IL1B NFKB1 NFKBIA
23
Show member pathways
12.91 CASP3 CHUK JUN NFKB1 NFKBIA
24
Show member pathways
12.89 CHUK EGFR MET NFKB1 PAK1 PTPN11
25
Show member pathways
12.89 CASP3 JUN MET NFKB1 NFKBIA PAK1
26
Show member pathways
12.88 CHUK EGFR MET NFKB1 NFKBIA PTPN11
27
Show member pathways
12.87 CASP3 CCL5 CHUK CXCL1 CXCL8 EGFR
28
Show member pathways
12.86 CHUK EGFR IL1B MET NFKB1 NFKBIA
29
Show member pathways
12.86 CASP3 CHUK EGFR IL1B JUN NFKB1
30
Show member pathways
12.84 CASP3 CHUK EGFR IFNGR1 IL1B JUN
31
Show member pathways
12.78 CXCL8 EGFR IFNGR1 IL1B PTPN11
32
Show member pathways
12.77 CHUK CXCL1 EGFR IL1B NFKB1 NFKBIA
33 12.75 CCL5 CHUK IL1B NFKB1 NFKBIA NOD1
34
Show member pathways
12.74 CHUK JUN NFKB1 NFKBIA PAK1
35
Show member pathways
12.74 CASP3 CHUK CXCL1 CXCL8 IFNGR1 JUN
36
Show member pathways
12.73 CASP3 CHUK EGFR JUN NFKB1 NFKBIA
37
Show member pathways
12.72 CHUK JUN NFKB1 NFKBIA PTPN11
38
Show member pathways
12.7 CASP3 CHUK IL1B JUN NFKB1 NFKBIA
39
Show member pathways
12.67 EGFR JUN MET NFKB1 PAK1 PTPN11
40
Show member pathways
12.66 CASP3 IFNGR1 JUN PAK1 PTPN11
41
Show member pathways
12.64 CASP3 CCL5 CHUK CXCL8 IFNGR1 IL1B
42
Show member pathways
12.63 CHUK JUN NFKB1 NFKBIA PAK1 PTPN11
43
Show member pathways
12.63 CHUK IFNGR1 IL1B JUN NFKB1 NFKBIA
44
Show member pathways
12.63 CHUK IL1B JUN NFKB1 NFKBIA PAK1
45
Show member pathways
12.62 CHUK IL1B MUC6 NFKB1 NFKBIA PAK1
46
Show member pathways
12.6 CHUK EGFR GAST JUN NFKB1 NFKBIA
47
Show member pathways
12.6 CASP3 CHUK IL1B JUN NFKB1 NFKBIA
48
Show member pathways
12.59 CHUK JUN NFKB1 NFKBIA PAK1 PTPN11
49
Show member pathways
12.58 CHUK JUN NFKB1 NFKBIA PAK1
50
Show member pathways
12.56 CASP3 EGFR JUN MET PAK1

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CCL5 CXCL1 CXCL8 EGFR GAST IL1B
2 I-kappaB/NF-kappaB complex GO:0033256 8.96 NFKB1 NFKBIA

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.97 CCL5 EGFR IL1B MET PAK1
2 regulation of cell proliferation GO:0042127 9.95 CXCL1 CXCL8 EGFR JUN NFKBIA
3 T cell receptor signaling pathway GO:0050852 9.92 CHUK NFKB1 NFKBIA PAK1
4 positive regulation of cell migration GO:0030335 9.92 ADAM10 CCL5 EGFR IL1B PAK1
5 wound healing GO:0042060 9.88 CASP3 EGFR PAK1
6 Fc-epsilon receptor signaling pathway GO:0038095 9.88 CHUK JUN NFKB1 NFKBIA PAK1
7 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.87 CHUK NFKBIA NOD1
8 liver development GO:0001889 9.87 EGFR JUN MET
9 cellular response to interleukin-1 GO:0071347 9.84 CCL5 CXCL8 NFKB1
10 chemokine-mediated signaling pathway GO:0070098 9.84 CCL5 CXCL1 CXCL8
11 response to organic substance GO:0010033 9.84 CASP3 CHUK JUN PAK1
12 neutrophil chemotaxis GO:0030593 9.83 CCL5 CXCL8 IL1B
13 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 CHUK NFKB1 NFKBIA
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 CHUK IL1B NFKB1 NFKBIA NOD1
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 CCL5 EGFR JUN
16 cellular response to mechanical stimulus GO:0071260 9.81 EGFR IL1B NFKB1 PTPN11
17 learning or memory GO:0007611 9.8 CASP3 EGFR PTPRZ1
18 cellular response to organic cyclic compound GO:0071407 9.8 CASP3 CCL5 IL1B NFKBIA
19 cellular response to tumor necrosis factor GO:0071356 9.8 CCL5 CHUK CXCL8 NFKB1 NFKBIA
20 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 CCL5 EGFR JUN MET NOD1 PTPN11
21 inflammatory response GO:0006954 9.8 CCL5 CHUK CXCL1 CXCL8 IL1B NFKB1
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.79 EGFR IL1B NOD1
23 protein kinase B signaling GO:0043491 9.79 CCL5 CHUK IL1B
24 cellular response to reactive oxygen species GO:0034614 9.77 CHUK EGFR JUN
25 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 CHUK MUC6 NFKB1 NFKBIA PAK1
26 cellular response to cadmium ion GO:0071276 9.76 CHUK EGFR JUN
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.75 CCL5 IL1B NFKBIA
28 response to tumor necrosis factor GO:0034612 9.73 ADAM10 CASP3 CCL5
29 eyelid development in camera-type eye GO:0061029 9.7 EGFR JUN
30 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.69 CCL5 CXCL8
31 hepatocyte growth factor receptor signaling pathway GO:0048012 9.68 MET PAK1
32 negative regulation by host of viral transcription GO:0043922 9.68 CCL5 JUN
33 positive regulation of T cell chemotaxis GO:0010820 9.67 ADAM10 CCL5
34 neutrophil activation GO:0042119 9.67 CCL5 CXCL8
35 response to muscle stretch GO:0035994 9.63 JUN NFKB1 NFKBIA
36 interleukin-1-mediated signaling pathway GO:0070498 9.55 CHUK IL1B NFKB1 NFKBIA NOD1
37 response to lipopolysaccharide GO:0032496 9.5 CASP3 CHUK CXCL1 CXCL8 IL1B JUN
38 cytokine-mediated signaling pathway GO:0019221 9.23 CASP3 CCL5 CXCL1 CXCL8 IFNGR1 IL1B
39 signal transduction GO:0007165 10.3 CXCL1 CXCL8 EGFR GAST IFNGR1 IL1B
40 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 CHUK EGFR IL1B JUN MET NFKB1
41 apoptotic process GO:0006915 10.11 CASP3 IL1B NFKB1 NFKBIA NOD1 PAK1
42 positive regulation of cell proliferation GO:0008284 10.1 ADAM10 EGFR IL1B JUN PAK1
43 intracellular signal transduction GO:0035556 10.08 CASP3 CXCL1 CXCL8 EGFR NOD1
44 positive regulation of transcription, DNA-templated GO:0045893 10.08 CHUK EGFR IL1B JUN NFKB1 NFKBIA
45 negative regulation of apoptotic process GO:0043066 10.08 CASP3 EGFR JUN MET NFKB1 NFKBIA
46 immune response GO:0006955 10.07 CCL5 CHUK CXCL1 CXCL8 IL1B
47 regulation of signaling receptor activity GO:0010469 10.06 CCL5 CXCL1 CXCL8 GAST IL1B

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ADAM10 CASP3 CCL5 CHUK CXCL8 EGFR
2 protein homodimerization activity GO:0042803 9.85 ADAM10 CCL5 CHUK JUN NFKB1 NOD1
3 protein kinase activity GO:0004672 9.8 CCL5 CHUK EGFR MET PAK1
4 cytokine activity GO:0005125 9.62 CCL5 CXCL1 CXCL8 IL1B
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGFR MET PTPN11
6 chemokine activity GO:0008009 9.33 CCL5 CXCL1 CXCL8
7 identical protein binding GO:0042802 9.23 CCL5 CHUK EGFR JUN MET NFKB1

Sources for Helicobacter Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....